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We evaluated measures to protect healthcare workers (HCWs) in Vancouver, Canada,
where variants of concern (VOC) went from <1% VOC in February 2021 to >92% in mid-
May. Canada has amongst the longest periods between vaccine doses worldwide, despite
Vancouver having the highest P.1 variant rate outside Brazil.
Methods
With surveillance data since the pandemic began, we tracked laboratory-confirmed SARS-
CoV-2 infections, positivity rates, and vaccine uptake in all 25,558 HCWs in Vancouver
Coastal Health, by occupation and subsector, and compared to the general population. Cox
regression modelling adjusted for age and calendar-time calculated vaccine effectiveness
(VE) against SARS-CoV-2 in fully vaccinated (� 7 days post-second dose), partially vacci-
nated infection (after 14 days) and unvaccinated HCWs; we also compared with unvacci-
nated community members of the same age-range.
Findings
Only 3.3% of our HCWs became infected, mirroring community rates, with peak positivity of
9.1%, compared to 11.8% in the community. As vaccine coverage increased, SARS-CoV-2
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infections declined significantly in HCWs, despite a surge with predominantly VOC; unvacci-
nated HCWs had an infection rate of 1.3/10,000 person-days compared to 0.89 for HCWs
post first dose, and 0.30 for fully vaccinated HCWs. VE compared to unvaccinated HCWs
was 37.2% (95% CI: 16.6–52.7%) 14 days post-first dose, 79.2% (CI: 64.6–87.8%) 7 days
post-second dose; one dose provided significant protection against infection until at least
day 42. Compared with community infection rates, VE after one dose was 54.7% (CI: 44.8–
62.9%); and 84.8% (CI: 75.2–90.7%) when fully vaccinated.
Interpretation
Rigorous droplet-contact precautions with N95s for aerosol-generating procedures are
effective in preventing occupational infection in HCWs, with one dose of mRNA vaccination
further reducing infection risk despite VOC and transmissibility concerns. Delaying second
doses to allow more widespread vaccination against severe disease, with strict public
health, occupational health and infection control measures, has been effective in protecting
the healthcare workforce.
Introduction
Healthcare workers (HCWs) worldwide face occupational risk of infectious disease [1].
COVID-19 has highlighted this risk, particularly in the early stages of the pandemic when per-
sonal protective equipment (PPE) was lacking in many settings [2,3], compounding the mental
health impacts of working on the frontline [4,5]. In many settings globally, HCWs have contin-
ued to provide patient care often in exhausting long shifts, and amidst fear of becoming
infected and transmitting to family, friends, patients and co-workers, sometimes with new
responsibilities and facing emotionally fraught decisions. Tragic deaths of medics and front-
line healthcare workers continue to occur across the globe, despite the recognition that pro-
tecting the healthcare workforce is a prerequisite to the safety of patients and the health of the
population at large.
Infection rates have been relatively low in the Canadian healthcare workforce [6] compared
to elsewhere [7,8], with a positivity rate of 6.5% by September 2020, no higher than for the gen-
eral Canadian population. Nonetheless, with growing concern about the possibility of greater
airborne transmission [9,10], especially in the context of variants of concern (VOC), vigilance
regarding protecting HCWs remains important in Canada, as it is worldwide [11]. While com-
binations of PPE and other non-pharmaceutical interventions are thought to be useful, there is
increasing consensus that the most effective means of protecting HCWs is vaccination. Just
how effective the various non-pharmaceutical interventions have been, and what the implica-
tions are for their ongoing application now that vaccines are available, are still topics of impor-
tant debate. Moreover, while it is increasingly well-established that the commonly approved
vaccines protect against severe illness [12], there has been no real-world data to date on the
performance of vaccines against the P.1 variant, and the issues of how long a single dose of a
two-series vaccine regiment remains protective against infection beckons further research.
HCWs were amongst the first groups to be vaccinated in the province of British Columbia
(BC) in Canada, and thus serve not only as a population to be studied with respect to their
own protection but also as a sentinel population to assess vaccine effectiveness, compared to
the general population. During this period, the dominant variants changed from <1% VOC to
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>92%, with the B1.1.7 and P.1 variants dominating; Vancouver, BC was documented at that
time as having the highest rate of P.1 variant outside of Brazil [13].
This study therefore had two main objectives. First, we tracked the risk of COVID-19 infec-
tions in our cohort of HCWs compared to the general population since the beginning of the
pandemic, examining risk by subsector and occupational group, to assess the effectiveness of
the occupational precautions implemented to date. Second, we sought to examine the impact
of the mRNA vaccine–including delaying the second dose–on COVID-19 infection in HCWs
in a jurisdiction with high levels of the P.1 variant [13], reported to be 2.5-times more trans-
missible than the wild variant [14].
Methods
Setting and study population
British Columbia, as all Canadian provinces, offers universal healthcare coverage through a
single-payer system, with all residents offered a Personal Health Number (PHN); non-perma-
nent residents, including temporary foreign workers, refugees and undocumented immigrants
are also able to obtain testing and vaccination free of charge, with a numeric identifier assigned
to them for COVID-19 testing and vaccination purposes. Vancouver Coastal Health (VCH)
and Fraser Health Authority (FHA) cover the greater Vancouver metropolitan area in BC.
VCH provides all laboratory, community, hospital and long-term care (LTC) services to more
than one million people. Public health measures during the pandemic included COVID-19
PCR test turnaround times of less than 24-hours, isolation within 24 hours of a positive test,
and prompt isolation of close contacts for 10 days after symptom onset (20 days for hospital-
ized cases), as well as limits on travel, indoor activities and outdoor gatherings as needed to
keep the caseload down and avoid pressure on the healthcare system.
Infection prevention and control (IPAC) measures starting March 29, 2020, required
HCWs to wear a medical mask (ASTM level 1, 2 or 3), eye protection and gloves for all direct
patient care, in addition to droplet and contact precautions when within 2 meters of COVID-
19 suspect or confirmed patients. Use of an N95 or equivalent respirator was permitted based
on a HCW’s point-of-care risk assessment (PCRA) and was required when an aerosol generat-
ing medical procedure (AGMP) was performed on a positive or suspected COVID-19 patient.
From November 4, 2020, all visitors and HCWs were required to wear a medical mask in all
common areas. Cotton or non-approved masks were not permitted and double masking was
strongly discouraged. There were no PPE disruptions during the pandemic, although extended
use of facial PPE of up to 4 hours was encouraged. IPAC personnel ensured optimal adminis-
trative and engineering controls, ongoing staff instruction and rapid response to outbreaks.
PPE measures were communicated in regular staff forums and bulletins plus targeted forums
for medical staff.
In addition to the existing provincial occupational health and local Employee Health and
Safety services, VCH established the Physicians Occupational Safety and Health (POSH) unit
to service medical staff, providing prompt access to expert advice, as well as exposure notifica-
tions and assessments, and contact tracing for this often harder-to-reach group. POSH also
conducts overall surveillance of HCW infection and vaccine rates within VCH, promoting vac-
cination and sending reminders to medical staff when eligible for vaccination with first or sec-
ond dose.
Immunizations against COVID-19 began on December 15, 2020. Dose 1 was given first to
LTC staff, residents and essential visitors, followed by highest risk acute HCWs (Emergency
room, Intensive care unit and COVID medical unit staff) in late December 2020 and early
2021. Initially dose 2 was given 35 days after dose 1. The inter-dose interval was lengthened to
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42 days in February 2020 then to 4 months (16 weeks) in early March 2021 in an effort to pro-
tect a greater number of people from severe disease and death [15] at a time of limited vaccine
supply. By the end of the observation period for this study (May 13, 2021), almost all HCWs in
this jurisdiction had been offered at least a single dose of vaccination, with some workers
receiving 2 doses. Virtually all HCWs were vaccinated with either the Pfizer-BioNTech
(93.3%) or Moderna (6.6%) COVID-19 vaccine (mRNA-1273). There were 310 HCWs (0.1%)
who received AstraZeneca vaccine and they were excluded from our cohort. Vaccination of
the general public started in February 2021, beginning with homeless and unstably housed,
older age-groups and the clinically extremely vulnerable, as well as Indigenous nations, then
essential workers and later high prevalence areas, working through the BC ethical framework
[16].
Our HCW cohort includes all active healthcare employees (nurses, care aids/licensed prac-
tical nurses, allied health professionals, support staff, administrators, and other employees) as
well as contracted medical staff (physicians, nurse practitioners, midwives, dentists, other
medical staff) who worked in VCH between March 15, 2020 and May 13, 2021. Non-medical
contractors (e.g. cleaning and food service staff) were not included in the database.
Database and analysis
All COVID-19 vaccines provided in BC are recorded in a provincial database by PHN and
other identifiers, regardless of immunization site. COVID-19 testing and results of PCR are
updated daily, and used for prompt contact tracing and public health surveillance, in conjunc-
tion with the BC Centre for Disease Control (BCCDC). Data on HCW infection rates and vac-
cinations are also extracted daily to populate the occupational health database for HCWs,
which includes their birthdate, sex, occupation and work location, among other variables such
as respirator fit-testing results. Data extracted from this database are used for regular occupa-
tional health surveillance of all VCH HCW COVID-19 infections as well as monitoring and
promoting vaccine uptake.
Community COVID-19 values and vaccination rates were collected from BCCDC, and the
occupational health database was used for HCW infections and vaccination data. We plotted
the COVID-19 rate in the VCH health workforce compared to the general population of simi-
lar age range, calculated over a moving 7-day period from March 1, 2020 to May 13, 2021. The
population denominator was retrieved from Statistics Canada [17] grouped by age and health
service regions. The data were merged, summarized and plotted using R (version 4.0.5). The
combined data from VCH and FHA were used for community comparison for VCH HCWs,
as VCH staff live in the larger Vancouver area which spans both health authorities.
To assess vaccine effectiveness against COVID-19 infections, all 25,558 VCH healthcare
workers were classified according to vaccination status over the period of observation. For the
150-day interval from December 15, 2020 to May 13, 2021, each HCW had the period stratified
into days unvaccinated, days vaccinated with one dose, and days vaccinated with two doses,
allowing 14 or 7 days for vaccine effect for one or two doses respectively, to allow comparison
with similar studies [18] assessing vaccine effectiveness. The 442 VCH healthcare workers who
tested positive prior to December 15, 2020 were excluded from further analysis. A Cox regres-
sion model was fitted to the data adjusting for age and calendar time, and the proportional
hazards assumption was verified.
Results were further assessed based on care sector and occupational categories. For the
cumulative incidence plot, a HCW counted as positive the day that they tested positive or
would be right-censored 14 days after the first dose or 7 days after the second dose if they did
not test positive prior to the end of the period (May 13, 2021). The unvaccinated classification
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had an origin time (t = 0) of December 15, 2020; the one dose classification had an origin time
14 days after the first dose; and the two-dose classification had an origin time 7 days after the
second dose. A log-rank test was performed to test whether there was a significant difference
between the incidence curves.
Ethical approval was provided by the Behavioural Ethics Review Board at the University of
British Columbia under certificate H21-01138. This work was secondary analysis of occupa-
tional health data in which all information was anonymized before being extracted for analysis;
individual consent was not required.
Results
The rates of positive COVID-19 PCR tests per 100,000 population are shown by date in Fig 1,
along with major points of interventions to protect HCWs. It can be seen that other than very
early in the pandemic, before PPE guidance was provided and widely implemented, infection
rates in HCWs paralleled those of the population at large, dramatically decreasing below that
of the community at large as vaccination of HCWs was quickly rolled-out at a faster pace than
in the general population. As the third surge, driven in part by a high proportion of the P.1 var-
iant, was quickly brought under control through public health interventions including more
widespread vaccination coverage of the population, the community rates fell, but HCW rates
still remained well below those of the background population.
To account for preferential access to testing by HCWs during the early period of the pan-
demic, Fig 2 shows the positivity rate in HCWs as compared to the background population,
suggesting that the high peak in HCW at the beginning of the pandemic shown in Fig 1 is
Fig 1. COVID-19 incidence rates and vaccine coverage in healthcare workers of Vancouver Coastal Health compared to adjusted general population in area of
residence over time.
https://doi.org/10.1371/journal.pone.0254920.g001
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likely due more to easier access of HCWs to COVID-19 testing. Positivity rates for our cohort
of HCWs during the first wave (March 1- June 1, 2020) were 2.35% (95% CI, 1.94–2.84) while
population rates were 2.27% (95% CI, 2.17–2.36). These figures similarly show a flat risk for
HCWs, despite a community surge near the end of this observation period.
By the end of the observation period, 22,118 (86.5%) of HCWs had received at least one
dose of vaccine, 7,328 (28.7%) had received two doses, with an average time between doses of
46.9 days (SD 18.7), leaving 3,440 (13.5%) unvaccinated. Table 1 shows COVID-19 rates and
vaccine status for active employees, by occupation at the end of our observation period.
Fig 2. COVID-19 positivity rate and vaccine coverage in in healthcare workers of Vancouver Coastal Health compared to general population in area of residence
over time.
https://doi.org/10.1371/journal.pone.0254920.g002
Table 1. COVID-19 infection rate and vaccine status for VCH HCWs by occupation by May 13, 2021.
Occupation (n) Cumulative COVID-19 rate n (%) Fully vaccinated n (%) Partially vaccinated n (%) Unvaccinated n (%)
Nurses (7,637) 247 (3.2%) 2,274 (29.8%) 4,433 (58.0%) 930 (12.2%)
LPN/Care Aide (5,759) 299 (5.2%) 2,482 (43.1%) 2,347 (40.8%) 930 (16.1%)
Administration (4,314) 114 (2.6%) 405 (9.4%) 3,137 (72.7%) 772 (17.9%)
Allied Health (3,906) 85 (2.2%) 820 (21.0%) 2,587 (66.2%) 499 (12.8%)
Medical staff (3,182) 68 (2.1%) 1,353 (42.5%) 1,700 (53.4%) 129 (4.1%)
Support staff (827) 35 (4.2%) 120 (14.5%) 548 (66.3%) 159 (19.2%)
Other or Unknown (950) 27 (2.8%) 210 (22.1%) 609 (64.1%) 131 (13.8%)
Grand Total (25,558) 837 (3.3%) 7,328 (28.7%) 14,790 (57.9%) 3,440 (13.5%)
�worked between March 15, 2020 –May 13, 2021. Excludes non-medical contract workers. An individual could have positions in multiple job classes, so can be counted
in multiple rows. Grand total only counts each HCW once.
https://doi.org/10.1371/journal.pone.0254920.t001
PLOS ONE Protecting health workers: Non-pharmaceutical interventions and vaccine effectiveness
PLOS ONE | https://doi.org/10.1371/journal.pone.0254920 July 16, 2021 6 / 14
The crude cumulative population rate was 4.0%, or 4.4% when age-adjusted to match the
workforce demographics, to allow comparison with our HCW cohort. By May 13, 2021, 3.3%
of the VCH health workforce had tested positive for COVID-19, ranging from 3.2% in the
acute sector to 4.6% in the long-term care sector; the highest risk occupational group was
Licensed Practical Nurses and Care Aides (5.2%) and the lowest, medical staff (2.1%). During
this time period, there was a shift from a rate of<1% VOC in early February to a high rate of
two variants of concern (VOC) the B1.1.7 and P.1 variants–representing >92% of all infections
by study closure, approximately evenly split between B.1.1.7 and P.1. [19].
There were 390 COVID-19 cases among active HCWs between Dec 15, 2020, and May 13,
2021. Of the 390 HCWs who became infected, 276 (70.8%) were unvaccinated or had received the
first dose<14 days prior to their positive test, 98 (25.1%) tested positive 14 days or more after the
first dose but before 7 days after the second dose, and 16 (4.1%) tested positive 7 days or more
after the second dose (Table 2). Rates continued to decline despite climbing community rates.
The difference in COVID-19 rates between unvaccinated, vaccinated with one dose and
fully vaccinated HCWs is shown in Table 3, where positive test results that occurred before 2
weeks after the first dose are counted in the unvaccinated category; similarly, positive tests that
occur before 1 week after the 2nd dose are counted in the 1st dose category.
Rates of infection during the observation period were 1.33 per 10,000 person-days in unvac-
cinated HCWs, and 0.89 and 0.30 per 10,000 person-days for partially and fully vaccinated
HCWs respectively (Table 3). This represents unadjusted reductions of COVID-19 of 33.2%
(95% CI, 15.9% to 47.0%) and 77.6% (95% CI, 62.9% to 86.5%) for partially and fully vacci-
nated HCWs respectively. Compared with the unvaccinated community rates, unadjusted
reductions were 54.7% (95% CI, 44.8% to 62.9%) and 84.8% (95% CI, 75.2% to 90.7%) for par-
tially and fully vaccinated HCWs. These reductions are significant at 95% confidence, except
for the interval comparing unvaccinated HCWs to those�42 days after the first dose, where
reductions seem to be much smaller but the size of the population under observation is too
small to make definitive statements in this regard. The Cox regression model, adjusted for age
in years and calendar time, showed a reduction of COVID-19 infections of 37.2% (95% CI,
16.6 to 52.7%)�14 days after the first dose and 79.2% (95% CI, 64.6 to 87.8%)�7 days after
the second dose. The cumulative infection rate of COVID-19 over time of unvaccinated, vacci-
nated�14 days with one dose and vaccinated�7 days with two doses is shown in Fig 3. A log-
rank test shows that the incidence curves are significantly different (p< 0.001).
The vaccine effectiveness over time for partially and fully-vaccinated HCWs relative to the
unvaccinated healthcare worker population, is shown in Fig 4.
Table 2. COVID-19 positive tests after vaccination in VCH HCWs from December 15, 2020.
When positive test occurred Count Days from last dose to positive test
Tested positive�14 days after first dose of vaccine 98 (25.1%) Median 47 days (IQR 33–61; Range 14–
106)
Mean 48.1 days (95% CI 43.9–52.3)
Tested positive�7 days after second dose of vaccine 16 (4.1%) Median 54 days (IQR 44–62; Range
8–87)
Mean 53.1 days (95% CI 43.2–62.9)
Tested positive when unvaccinated or <14 days after first
dose
276 (70.8%) --
Before 1st dose 220 (56.4%) --
< 14 days after first dose 56 (14.4%) Median 8 days (IQR 4–9; Range 1–13)
Mean 7.0 days (95% CI 6.1–7.9)
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Discussion
Protecting the healthcare workforce is an enduring priority. As such, ongoing vigilance on the
adequacy of HCWs protection is essential, particularly in the face of growing concerns about
Fig 3. Cumulative incidence of COVID-19 infection comparing unvaccinated, partially vaccinated and fully vaccinated healthcare workers of Vancouver Coastal
Health over time.
https://doi.org/10.1371/journal.pone.0254920.g003
Table 3. COVID-19 positive tests by vaccination status over time in VCH HCWs and community (aged 20–69) from December 15, 2020 to May 13, 2021. The
adjusted rate is calculated using Cox regression, adjusting for age and calendar time.

















2020 to May 13,
2021




Before 1st dose 220 1,772,575 1.24 -- -- --
< 14 days after 1st
dose
56 298,634 1.88 -- -- --





39 578,496 0.67 49.4% (29.2% to 63.8%) -- 65.7% (53.0% to
74.9%)
� 42 days after 1st
dose
59 523,354 1.13 15.4% (-12.1% to 36.1%) -- 42.6% (25.9% to
55.5%)




� 7 days after 2nd
dose
16 536,300 0.30 77.6% (62.9% to 86.5%) 79.2% (64.6% to 87.8%) 84.8% (75.2% to
90.7%)
https://doi.org/10.1371/journal.pone.0254920.t003
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VOC and airborne transmission. Our data are consistent with the premise that the PPE recom-
mendations in place (generally droplet-contact except where an AGMP is being performed)
have provided good protection to workers, as part of a comprehensive rigorously implemented
IPAC, Public Health and Occupational Health integrated program, with a permissive policy of
N95 use based on a PCRA. While surveillance data lack details of which workers chose to wear
an N95, or where they did so, this study has shown that PPE policies in place have worked well
in our jurisdiction regardless of the proportion of viral transmission that may be airborne, and
regardless of the high proportion of more transmissible variants.
While our relatively high rate of HCWs testing positive early in the pandemic may reflect a
truly higher risk, it may be largely attributable to the selective testing strategy (due to limita-
tions in testing capacity), which gave health workers preferential access to testing early in the
pandemic. This hypothesis is supported by the observation that HCW positivity rates were
similar to the background population. Increased case finding during outbreaks may also
explain the differences in incident rates seen. Emecen and colleagues [20] showed that the
serial interval and incubation periods of COVID-19 in HCWs were shorter than in the general
population, which they suggest could be attributable to more rigorous contact tracing and iso-
lation of infected HCWs [20].
Nonetheless, higher rates in HCWs with more extensive physical contact with patients (e.g.
LPN, care aides) compared to others (administrators and medical staff) are concerning and
may indeed suggest a role for occupational exposure in this group of workers. Case-control
studies of risk factors for COVID-19 among HCWs [21,22] found that direct care to COVID-
19 patients, unmasked close interaction with colleagues, and inappropriate use or shortage of
PPEs were significant predictors of increased occupational risk among HCWs, along with
Fig 4. Vaccine effectiveness (mRNA vaccine) comparing one dose and two doses over time.
https://doi.org/10.1371/journal.pone.0254920.g004
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non-work-related risk factors. However, as suggested by others studies [23,24], the higher risk
in this group of workers may also be explained by differences in socio-economic status and
demographic factors which impacts variables such as private car use (versus public transit or
carpooling), household composition, community of residence, and other important social
determinants of health. We have a nested case-control study in progress to investigate the role
of these putative risk factors in our cohort of VCH HCWs to supplement the rigorous analysis
of surveillance data reported here. Regardless of whether the higher risk is predominantly
attributable to community-based or workplace exposure, our data strongly indicate the need
to prioritize these higher-risk workers in vaccination programs.
Our study shows 33.2% (95% CI, 15.9 to 47.0%) vaccine effectiveness against PCR-con-
firmed infections�14 days after first dose, and 77.6% (95% CI, 62.9 to 86.5%) effectiveness�7
days after the second dose when compared to unvaccinated HCWs, even with high rates of the
B1.1.7 and P.1 variants. When compared to age-adjusted unvaccinated general public rates, we
found vaccine effectiveness of 54.7% (95% CI, 44.8 to 62.9%)�14 days after the first dose, ris-
ing to 84.8% (95% CI, 75.2 to 90.7%)�7 days after the second dose. This represents a conser-
vative estimate of vaccine effectiveness as infections that occur in the 14–21 period post first
dose of vaccine may be due to infections acquired in the two weeks before antibodies devel-
oped. Moreover, the impact of vaccination on severity of disease was not captured in this anal-
ysis, and that infection rates are arguably of less concern than hospitalizations and no deaths
occurred in our healthcare workforce.
Our findings are similar to other studies [18,25–27], which show vaccine-associated infec-
tion rate reductions following vaccination with increasing effectiveness from day 14 after first
dose. For example, Dagan et al. [28] estimated vaccine effectiveness 14–20 days post first dose
as 46% (95% CI, 40–51); and 92% (95% CI, 88–95) post second dose. Some studies showed
higher rate reduction in vaccinated HCWs than our study [28,29]; this is likely explained by
lower infection rates in our population: 1/10th of rates of HCW infected reported elsewhere
(1.3 per 10,000 person-days in our cohort compared to 13.8 per 10,000 in a US cohort) [12]
likely reflecting differences both in work and community transmission risk. Our lower infec-
tion rates in HCWs compared to studies in other settings add to the evidence that rigorous
implementation of public health, occupational health and infection control measures can
indeed keep HCWs protected at work and at home.
The higher rate of COVID-19 in the first two weeks following vaccination may be partly
due to people dropping their guard thinking they are protected when antibodies have not yet
developed, or individuals already infected and in the latency period at the time they were vacci-
nated. Likewise, because of changes in timing of a second dose the higher rate of infection in
the period between the first and second doses, may be partially explained by the increasing
community rates at the time longer-interval vaccine timing was occurring. Infections reached
their nadir in mid-February, followed by an exponential rise in rates until mid-April, possibly
partly accounting for the lower effectiveness reported for a single dose. This may bias against
the efficacy of the single dose. Regardless, the need to ensure vigilance (at work and at home)
in the 2-3-week period following vaccination is highlighted by our findings, as is the critical
need for HCWs to receive two doses of vaccine to achieve excellent protection.
Unlike studies in other locations [30–32], in our jurisdiction fewer than 1% of all HCWs
abstained from being vaccinated for medical or personal reasons, thus vaccine hesitancy is
likely not a large issue. That higher risk occupational groups in our cohort–namely Licensed
Practical Nurses and Care Aides–had slightly lower vaccination rates compared to lower risk
healthcare worker groups is troubling. This may reflect less effective communication and out-
reach strategies to these workers compared to what nurses and medical staff receive, greater
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difficulty in organizing vaccine appointments given work schedules, or greater vaccine hesi-
tancy; further research is needed to understand the reasons for these differences.
Hall et al. [29] in their cohort of healthcare workers in England found their Pfizer vaccina-
tion was effective against the B1.1.7 strain, circulating at the time in the UK; their testing strat-
egy in the UK was similar to ours with only symptomatic testing of HCWs conducted outside
of outbreaks. Ours is the only report, of which we are aware, showing real-world effectiveness
of vaccination in a population highly affected by the P.1 strain of SARS-CoV-2. While more
study is needed, our results indicate that: 1) rigorous infection control measures have been
effective in preventing occupational exposure; 2) vaccination has been effective in protecting
HCWs from the impact of the third surge in which two VOC (B1.1.7 and P.1) predominated;
3) protection with one dose has been almost as effective as two doses for the first 42 days at
least; and 4) the two-week period after vaccination is a high-risk period. The protection against
infection gained from the single dose of the vaccine suggests that delaying administering the
second dose to allow more people to have received at least one dose seems to have been well-
founded; these findings provide strong support for guidelines suggesting an interval of at least
up to 42 days between first and second dose [33]. A greater period of follow-up of our cohort
is needed before more definitive statements can be drawn from this work regarding longer
delays. Importantly, our study was not designed to assess real-world vaccine effectiveness
related to severe disease, hospitalization and death; due to a high degree of occupational pro-
tection, we did not see widespread severe disease and death in our healthcare workforce even
before the vaccination campaign began.
Overall, this study indicates that excellent protection can be achieved with predominantly
droplet-contact infection prevention and control measures with N95s where appropriate, com-
bined with prompt testing, tracing, isolation, and strong communication measures including
with contracted medical staff, along with public health interventions that reduce pressure on
the healthcare system. It further underlines the importance of the vaccination program, which
we found to be effective in protecting HCWs from infection even in the face of VOC. That vac-
cination is far from perfect also underlines the need for ongoing vigilance in continued occu-
pational protection, especially as variants continue to mutate and present new challenges.
Nonetheless this study should provide some reassurance that the current approach of combin-
ing vaccination programs with infection prevention and control measures employed with a
high degree of rigour, monitoring and communication, seems to indeed be effective to protect
the healthcare workforce.
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